丹七软胶囊对冠心病患者的心肌保护及血液流变学改善作用

Myocardial protection effect of Danqi soft capsule and its improving effect on hemorheology in patients with coronary heart disease

目的：探讨丹七软胶囊对冠心病患者的心肌保护及血液流变学改善的作用。方法：选择2013年12月~2014年12月我院收治的冠心病患者84例,患者被随机均分为常规治疗组（42例）和联合治疗组（42例,在常规治疗组的基础上加用丹七软胶囊治疗）。对两组患者治疗前后血液流变学指标、心电图及炎症因子[C反应蛋白（CRP）和肿瘤坏死因子α（TNF-α）]水平进行检测比较。结果：与治疗前比较,治疗后两组上述血液流变学指标均显著降低（P均〈0.05）,且与常规治疗组比较,联合治疗组全血高切黏度[（5.12±0.73）mPa/s比（4.47±0.86）mPa/s]、全血低切黏度[（7.36±1.32）mPa/s比（6.21±1.03）mPa/s]、血浆黏度[（1.47±0.31）mPa/s比（1.31±0.25）mPa/s]、红细胞聚集指数[（3.53±0.45）比（2.93±0.26）]和纤维蛋白原水平[（2.95±0.28）g/L比（2.08±0.24）g/L]降低更显著,P均〈0.05。联合治疗组的心电图总有效率显著高于常规治疗组（85.71%比57.14%,P〈0.05）。与治疗前比较,两组CRP和TNF-α水平均显著降低（P均〈0.05）,且与常规治疗组比较,联合治疗组CRP[（6.52±1.61）mg/L比（5.18±1.25）mg/L]和TNF-α水平[（283.28±18.28）pg/ml比（245.08±12.24）pg/ml]降低更显著,P均〈0.05。结论：丹七软胶囊联合常规疗法治疗冠心病,可明显改善血液流变学和降低相关炎症因子水平,有心肌保护作用,值得推广。

Objective： To explore improving effect of Danqi soft capsule on hemorheology in patients with coronary heart disease （CHD） and its myocardial protection effect. Methods： A total of 84 CHD patients treated in our hos- pital from Dec 2013 to Dec 2014 were enrolled. They were randomly divided into routine treatment group （n = 42） and combined treatment group （n = 42, received Danqi soft capsule therapy based on routine treatment group）. He- morheological indexes, ECG and inflammatory factor levels [C reactive protein （CRP）, tumor necrosis factor a （TNF-a）] were measured and compared between two groups before and after treatment. Results.. Compared with before treatment, above hemorheological indexes significantly reduced in both groups after treatment （P〈0.05 all）, compared with routine treatment group, there were significant reductions in high shear whole blood viscosity [ （5.12 ± 0.73） mPa/s vs. （4. 47 ± 0.86） mPa/s], low shear whole blood viscosity [ （7. 36 ± 1.32） mPa/s vs, （6. 21 ± 1.03） mPa/s], plasma viscosity [ （1.47 ± 0.31） mPa/s vs. （1.31 ± 0.25） mPa/s], erythrocyte aggregation index [ （3.53 ± 0.45） vs. （2.93 ± 0.26）] and fibrinogen level [ （2.95 ± 0.28） g/L vs. （2.08 ± 0. 24） g/L] in combined treatment group, P〈0.05 all. Total effective rate on ECG in combined treatment group was significantly higher than that of routine treatment group （85.71% vs. 57.14%, P〈0.05）. Compared with before treatment, CRP and TNF-a levels significantly reduced in both groups after treatment （P〈0.05 all）, compared with routine treatment group, there were significant reductions in levels of CRP [ （6.52 ± 1.61） mg/L vs. （5.18 ± 1.25） mg/L] and TNF- [ （283.28 ± 18. 28） pg/ml vs. （245.08 ±12.24） pg/ml] in combined treatment group, P〈0.05 all. Conclusion.. Danqi soft capsule combined routine treatment can significantly improve hemorheology and reduce related inflamma- tory factor levels, possess myocardial protection effect in CHD patients, which is worth extending.